Loading stock data…
ASTRAZENECA PLC ORD SHS $0.25 (AZN.L)
LSE14,298pGBX-20.00p (-0.14%)
Market ClosedLast close Jun 29
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at 14,298p with a market capitalization of $210.9B. Wall Street consensus targets 16,642p (21 analysts), implying a +16.4% move over the next 12 months. The stock is currently 9% below its 52-week high of 15,732p, remaining 4.6% above its 200-day moving average. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +16.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | $13.59B↓ | $14.46B↓ | $15.19B↓ | $15.50B↑ | $15.29B |
| Gross Profit | $11.35B↓ | $11.98B↓ | $12.39B | $12.38B↓ | $12.61B |
| Operating Income | $3.67B↑ | $3.51B↓ | $3.58B↑ | $2.98B↓ | $4.25B |
| Net Income | $2.92B↑ | $2.45B↓ | $2.53B↑ | $2.33B↓ | $3.08B |
Peer Comparison
JNJUNHPFE
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$210.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
27.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Strong income play. Yield provides a meaningful total return floor.
175.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.48%
Volume
Today's trading volume
1.84M
Recent News
European Stocks Close Mixed in Monday Trading as Investors Stay on Sidelines, Weigh Tech Rout, Geopolitical Risks
European stock markets closed mixed in Monday trading, with investors remaining on the sidelines as
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
AstraZeneca (LSE:AZN) Stock Weighs Strong Run Against Cash Flow And Earnings Valuation Models
Curious whether AstraZeneca is priced attractively today, or if recent enthusiasm has already been baked into the stock. AstraZeneca shares last closed at £140.62, with returns of 6.9% over 7 days, 0.7% over 30 days, 3.5% year to date, 41.0% over 1 year, 32.9% over 3 years, and 78.7% over 5 years, which gives plenty of data points for anyone thinking about value and risk. Recent coverage around AstraZeneca has kept attention on its role in the global pharmaceuticals sector and how its...
AstraZeneca (LSE:AZN) Forms Five Year YMCA Cancer Partnership As Ultomiris Wins Priority Review
AstraZeneca (LSE:AZN) has agreed a new five year national partnership with YMCA of the USA to expand community based cancer education, screening, and survivorship support. The company also received US FDA Priority Review for Ultomiris in treating IgA nephropathy, a rare kidney disease. AstraZeneca operates as a global pharmaceuticals company with a focus on oncology and specialty medicines. A nationwide collaboration with YMCA of the USA connects its cancer portfolio directly with community...
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout
Jefferies has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and named the drugmaker a Franchise Pick, framing an approaching late-stage trial readout as the next major catalyst for the shares. The broker holds a price target of 18,000p, implying upside of around 30% to...